Victory over Gilead! California Court Rules HIV Drug Personal Injury Cases May Proceed

HIV/AIDS patients and advocates are celebrating a California court ruling that allows personal injury cases against Gilead Sciences Inc. over the drug companys years-long promotion of its TDF-based HIV/AIDS medications that cause permanent damage to kidneys and bones, to proceed.

In a ruling issued earlier today, the Honorable Carolyn B Kuhl, Judge of the Superior Court of California, County of Los Angeles rejected all but one of Gileads arguments in its demurrer seeking to have all the HIV/AIDS patients legal theories dismissed. Judge Kuhls well-reasoned opinion held that Plaintiffs’ allegations were sufficiently pled to move forward with all their tort claims, aside from strict liability.

In May 2018, California patients living with HIV filed a personal injury lawsuit against Gilead Sciences Inc. seeking to hold the Bay Area drug maker accountable for actions around its promotion of tenofovir disoproxil fumarates (TDFs) drug formulation, knowing a safer alternate, tenofovir alafenamide (TAF), existed; failure to warn patients of the damaging side effects of TDF; and active misrepresentation of TDFs efficacy and risks.

The legal actions, prepared by HIV Litigation Attorneys and Rutherford Law, were filed in May 2018 in Superior Court of the State of California for the County of Los Angeles, [Case No. BC702302, Personal Injury Claims; and Case No. BC 705063, Class Action Status], and each demands a jury trial. AHF is funding the litigation and will not receive any financial recovery from the lawsuit in excess of its actual costs.

WANT TO BUILD A FINANCIAL EMPIRE?

Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

The cases also assert that Gilead deliberately and maliciously suppressed from the market its alternate and newer formulation of the drug, TAF, in order to extend the patent lifeand salesof its existing medications that included TDF. Gilead earned over $18 billion in net profit in 2015.

This ruling is a tremendous victory for HIV/AIDS patients in their quest for justice regarding the life-threatening physical harm that Gilead has caused and we thank Judge Kuhl and the court for allowing these cases to proceed, said Arti Bhimani of HIV Litigation Attorneys, attorney for plaintiffs.

Gileads perverse motive of outsized profits and increased market share is not in line with patient health and safety and we are grateful that patients will now get their days in court, said Liza Brereton of HIV Litigation Attorneys, attorney for plaintiffs.

“Gilead has shown a disregard for its patients’ health in order to reap outsized profits from its TDF medications. I am happy the judge has allowed our case against Gilead to proceed,” said Plaintiff Michael Lujano.

Anyone interested in joining this lawsuit should visit www.hivlitigation.com or call HIV Litigation Attorneys at (323) 860-5230.

About AIDS Healthcare Foundation

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over one million individuals in 43 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare

MEDIA CONTACTS:
Ged Kenslea, Senior Director,
Communications, AHF
+1.323.791.5526 mobile [email protected]

Michelle Rutherford, Rutherford Law
+1.323.641.0784 work [email protected]